These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 37968718)

  • 1. A phase 1 open-label pilot study of low-dose interleukine-2 immunotherapy in patients with Alzheimer's disease.
    Faridar A; Eid AM; Thome AD; Zhao W; Beers DR; Pascual MB; Nakawah MO; Roman GC; Davis CS; Grundman M; Masdeu JC; Appel SH
    Transl Neurodegener; 2023 Nov; 12(1):54. PubMed ID: 37968718
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FUNDAMANT: an interventional 72-week phase 1 follow-up study of AADvac1, an active immunotherapy against tau protein pathology in Alzheimer's disease.
    Novak P; Schmidt R; Kontsekova E; Kovacech B; Smolek T; Katina S; Fialova L; Prcina M; Parrak V; Dal-Bianco P; Brunner M; Staffen W; Rainer M; Ondrus M; Ropele S; Smisek M; Sivak R; Zilka N; Winblad B; Novak M
    Alzheimers Res Ther; 2018 Oct; 10(1):108. PubMed ID: 30355322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ABT-126 monotherapy in mild-to-moderate Alzheimer's dementia: randomized double-blind, placebo and active controlled adaptive trial and open-label extension.
    Gault LM; Lenz RA; Ritchie CW; Meier A; Othman AA; Tang Q; Berry S; Pritchett Y; Robieson WZ
    Alzheimers Res Ther; 2016 Oct; 8(1):44. PubMed ID: 27756421
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of anidulafungin in the treatment of intra-abdominal candidiasis: a pooled analysis of patient-level data from 5 prospective studies.
    Sganga G; Wang M; Capparella MR; Tawadrous M; Yan JL; Aram JA; Montravers P
    Eur J Clin Microbiol Infect Dis; 2019 Oct; 38(10):1849-1856. PubMed ID: 31280481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 1 trial.
    Novak P; Schmidt R; Kontsekova E; Zilka N; Kovacech B; Skrabana R; Vince-Kazmerova Z; Katina S; Fialova L; Prcina M; Parrak V; Dal-Bianco P; Brunner M; Staffen W; Rainer M; Ondrus M; Ropele S; Smisek M; Sivak R; Winblad B; Novak M
    Lancet Neurol; 2017 Feb; 16(2):123-134. PubMed ID: 27955995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study.
    Winblad B; Andreasen N; Minthon L; Floesser A; Imbert G; Dumortier T; Maguire RP; Blennow K; Lundmark J; Staufenbiel M; Orgogozo JM; Graf A
    Lancet Neurol; 2012 Jul; 11(7):597-604. PubMed ID: 22677258
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A 12-month randomised pilot trial of the Alzheimer's and music therapy study: a feasibility assessment of music therapy and physical activity in patients with mild-to-moderate Alzheimer's disease.
    Matziorinis AM; Flo BK; Skouras S; Dahle K; Henriksen A; Hausmann F; Sudmann TT; Gold C; Koelsch S
    Pilot Feasibility Stud; 2023 Apr; 9(1):61. PubMed ID: 37076884
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bapineuzumab for mild to moderate Alzheimer's disease in two global, randomized, phase 3 trials.
    Vandenberghe R; Rinne JO; Boada M; Katayama S; Scheltens P; Vellas B; Tuchman M; Gass A; Fiebach JB; Hill D; Lobello K; Li D; McRae T; Lucas P; Evans I; Booth K; Luscan G; Wyman BT; Hua L; Yang L; Brashear HR; Black RS;
    Alzheimers Res Ther; 2016 May; 8(1):18. PubMed ID: 27176461
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and tolerability of donepezil 23 mg with or without intermediate dose titration in patients with Alzheimer's disease taking donepezil 10 mg: a multicenter, randomized, open-label, parallel-design, three-arm, prospective trial.
    Hong YJ; Han HJ; Youn YC; Park KW; Yang DW; Kim S; Kim HJ; Kim JE; Lee JH;
    Alzheimers Res Ther; 2019 May; 11(1):37. PubMed ID: 31039806
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety, Efficacy, and Feasibility of Intranasal Insulin for the Treatment of Mild Cognitive Impairment and Alzheimer Disease Dementia: A Randomized Clinical Trial.
    Craft S; Raman R; Chow TW; Rafii MS; Sun CK; Rissman RA; Donohue MC; Brewer JB; Jenkins C; Harless K; Gessert D; Aisen PS
    JAMA Neurol; 2020 Sep; 77(9):1099-1109. PubMed ID: 32568367
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term safety and tolerability of bapineuzumab in patients with Alzheimer's disease in two phase 3 extension studies.
    Ivanoiu A; Pariente J; Booth K; Lobello K; Luscan G; Hua L; Lucas P; Styren S; Yang L; Li D; Black RS; Brashear HR; McRae T
    Alzheimers Res Ther; 2016 Jun; 8(1):24. PubMed ID: 27334799
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term safety and tolerability of atabecestat (JNJ-54861911), an oral BACE1 inhibitor, in early Alzheimer's disease spectrum patients: a randomized, double-blind, placebo-controlled study and a two-period extension study.
    Novak G; Streffer JR; Timmers M; Henley D; Brashear HR; Bogert J; Russu A; Janssens L; Tesseur I; Tritsmans L; Van Nueten L; Engelborghs S
    Alzheimers Res Ther; 2020 May; 12(1):58. PubMed ID: 32410694
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A pilot study of prednisone in Alzheimer's disease.
    Aisen PS; Marin D; Altstiel L; Goodwin C; Baruch B; Jacobson R; Ryan T; Davis KL
    Dementia; 1996; 7(4):201-6. PubMed ID: 8835883
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety, tolerability and immunogenicity of an active anti-Aβ
    Lacosta AM; Pascual-Lucas M; Pesini P; Casabona D; Pérez-Grijalba V; Marcos-Campos I; Sarasa L; Canudas J; Badi H; Monleón I; San-José I; Munuera J; Rodríguez-Gómez O; Abdelnour C; Lafuente A; Buendía M; Boada M; Tárraga L; Ruiz A; Sarasa M
    Alzheimers Res Ther; 2018 Jan; 10(1):12. PubMed ID: 29378651
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted delivery of nerve growth factor to the cholinergic basal forebrain of Alzheimer's disease patients: application of a second-generation encapsulated cell biodelivery device.
    Eyjolfsdottir H; Eriksdotter M; Linderoth B; Lind G; Juliusson B; Kusk P; Almkvist O; Andreasen N; Blennow K; Ferreira D; Westman E; Nennesmo I; Karami A; Darreh-Shori T; Kadir A; Nordberg A; Sundström E; Wahlund LO; Wall A; Wiberg M; Winblad B; Seiger Å; Wahlberg L; Almqvist P
    Alzheimers Res Ther; 2016 Jul; 8(1):30. PubMed ID: 27389402
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety, tolerability, pharmacokinetics and effects of diet on AD16, a novel neuroinflammatory inhibitor for Alzheimer's disease: a randomized phase 1 study.
    Peng D; Xu S; Zou T; Wang Y; Ouyang W; Zhang Y; Dong C; Li D; Guo J; Shen Q; Hu X; Zhou W; Li X; Qin Q
    BMC Med; 2023 Nov; 21(1):459. PubMed ID: 37996817
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer's disease: study protocol for a randomised controlled trial (ELAD study).
    Femminella GD; Frangou E; Love SB; Busza G; Holmes C; Ritchie C; Lawrence R; McFarlane B; Tadros G; Ridha BH; Bannister C; Walker Z; Archer H; Coulthard E; Underwood BR; Prasanna A; Koranteng P; Karim S; Junaid K; McGuinness B; Nilforooshan R; Macharouthu A; Donaldson A; Thacker S; Russell G; Malik N; Mate V; Knight L; Kshemendran S; Harrison J; Hölscher C; Brooks DJ; Passmore AP; Ballard C; Edison P
    Trials; 2019 Apr; 20(1):191. PubMed ID: 30944040
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapid improvement in verbal fluency and aphasia following perispinal etanercept in Alzheimer's disease.
    Tobinick EL; Gross H
    BMC Neurol; 2008 Jul; 8():27. PubMed ID: 18644112
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multicentre, randomised, open-label, parallel-group, clinical phase II study to evaluate immunonutrition in improving efficacy of immunotherapy in patients with metastatic non-small cell lung cancer, undergoing systematic nutritional counseling.
    Caccialanza R; Cereda E; Agustoni F; Klersy C; Casirati A; Montagna E; Carnio S; Novello S; Milella M; Pilotto S; Trestini I; Buffoni L; Ferrari A; Pedrazzoli P
    BMC Cancer; 2022 Nov; 22(1):1212. PubMed ID: 36434615
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Noradrenergic Add-on Therapy with Extended-Release Guanfacine in Alzheimer's Disease (NorAD): study protocol for a randomised clinical trial and COVID-19 amendments.
    Hoang K; Watt H; Golemme M; Perry RJ; Ritchie C; Wilson D; Pickett J; Fox C; Howard R; Malhotra PA
    Trials; 2022 Aug; 23(1):623. PubMed ID: 35915506
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.